Handelsbanken Fonder’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $34.7M | Buy |
205,871
+18,004
| +10% | +$2.67M | 0.1% | 172 |
|
|
2026
Q1 | $24.8M | Sell |
187,867
-13,000
| -6% | -$1.72M | 0.08% | 205 |
|
|
2025
Q4 | $28.5M | Buy |
200,867
+91,400
| +83% | +$13.2M | 0.09% | 201 |
|
|
2025
Q3 | $15.4M | Buy |
109,467
+5,500
| +5% | +$745K | 0.05% | 307 |
|
|
2025
Q2 | $13.1M | Buy |
103,967
+17,900
| +21% | +$2.05M | 0.05% | 317 |
|
|
2025
Q1 | $9.52M | Buy |
86,067
+59,200
| +220% | +$7.5M | 0.04% | 344 |
|
|
2024
Q4 | $3.67M | Hold |
26,867
| – | – | 0.01% | 496 |
|
|
2024
Q3 | $3.1M | Buy |
26,867
+4,600
| +21% | +$631K | 0.01% | 530 |
|
|
2024
Q2 | $3.06M | Sell |
22,267
-800
| -3% | -$110K | 0.01% | 488 |
|
|
2024
Q1 | $3.18M | Buy |
23,067
+4,200
| +22% | +$574K | 0.01% | 509 |
|
|
2023
Q4 | $2.49M | Buy |
18,867
+1,500
| +9% | +$173K | 0.01% | 515 |
|
|
2023
Q3 | $1.95M | Hold |
17,367
| – | – | 0.01% | 551 |
|
|
2023
Q2 | $1.64M | Sell |
17,367
-200
| -1% | -$19.5K | 0.01% | 585 |
|
|
2023
Q1 | $1.78M | Buy |
17,567
+4,400
| +33% | +$458K | 0.01% | 555 |
|
|
2022
Q4 | $1.57M | Sell |
13,167
-2,100
| -14% | -$246K | 0.01% | 555 |
|
|
2022
Q3 | $1.62M | Hold |
15,267
| – | – | 0.01% | 556 |
|
|
2022
Q2 | $1.49M | Hold |
15,267
| – | – | 0.01% | 586 |
|
|
2022
Q1 | $1.43M | Buy |
15,267
+5,100
| +50% | +$432K | 0.01% | 668 |
|
|
2021
Q4 | $866K | Sell |
10,167
-7,300
| -42% | -$672K | ﹤0.01% | 970 |
|
|
2021
Q3 | $1.68M | Hold |
17,467
| – | – | 0.01% | 675 |
|
|
2021
Q2 | $1.7M | Sell |
17,467
-600
| -3% | -$57.5K | 0.01% | 676 |
|
|
2021
Q1 | $1.76M | Hold |
18,067
| – | – | 0.01% | 643 |
|
|
2020
Q4 | $1.73M | Sell |
18,067
-201,900
| -92% | -$19.5M | 0.01% | 634 |
|
|
2020
Q3 | $21.2M | Buy |
219,967
+20,000
| +10% | +$2.31M | 0.16% | 138 |
|
|
2020
Q2 | $24.4M | Sell |
199,967
-4,033
| -2% | -$446K | 0.2% | 107 |
|
|
2020
Q1 | $17.7M | Buy |
204,000
+35,000
| +21% | +$3.43M | 0.38% | 72 |
|
|
2019
Q4 | $18.2M | Sell |
169,000
-35,000
| -17% | -$3.66M | 0.31% | 97 |
|
|
2019
Q3 | $18.4M | Buy |
204,000
+27,000
| +15% | +$2.52M | 0.37% | 81 |
|
|
2019
Q2 | $14.9M | Sell |
177,000
-30,000
| -14% | -$2.46M | 0.28% | 100 |
|
|
2019
Q1 | $18.2M | Buy |
207,000
+6,600
| +3% | +$552K | 0.35% | 76 |
|
|
2018
Q4 | $14.3M | Buy |
200,400
+35,400
| +21% | +$3.39M | 0.29% | 96 |
|
|
2018
Q3 | $20.3M | Buy |
165,000
+5,000
| +3% | +$567K | 0.38% | 83 |
|
|
2018
Q2 | $15.7M | Sell |
160,000
-6,000
| -4% | -$537K | 0.31% | 96 |
|
|
2018
Q1 | $13.8M | Buy |
166,000
+14,500
| +10% | +$1.22M | 0.27% | 99 |
|
|
2017
Q4 | $11.8M | Buy |
151,500
+3,500
| +2% | +$239K | 0.26% | 94 |
|
|
2017
Q3 | $9.07M | Hold |
148,000
| – | – | 0.21% | 101 |
|
|
2017
Q2 | $6.81M | Buy |
148,000
+28,000
| +23% | +$1.36M | 0.17% | 113 |
|
|
2017
Q1 | $5.2M | Buy |
120,000
+20,000
| +20% | +$857K | 0.14% | 115 |
|
|
2016
Q4 | $3.87M | Hold |
100,000
| – | – | 0.12% | 119 |
|
|
2016
Q3 | $5.06M | Buy |
100,000
+70,000
| +233% | +$3.49M | 0.15% | 118 |
|
|
2016
Q2 | $1.36M | Buy |
+30,000
| New | +$1.38M | 0.06% | 117 |
|
Other funds holding NBIX
Handelsbanken Fonder's NBIX Position: Q2 2026 in Review
Handelsbanken Fonder increased its Neurocrine Biosciences (NBIX) stake by 9.6% in Q2 2026, buying an estimated $2.67M and bringing the position to 205,871 shares worth $34.7M. The position accounts for 0.1% of the portfolio, ranked #172.
Handelsbanken Fonder first reported a position in NBIX in Q2 2016 and has held it in 41 quarters since. 388 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Handelsbanken Fonder held 205,871 shares of Neurocrine Biosciences worth $34.7M as of Q2 2026.
- Handelsbanken Fonder bought 18,004 Neurocrine Biosciences shares in Q2 2026, an estimated $2.67M.
- Neurocrine Biosciences made up 0.1% of Handelsbanken Fonder's portfolio in Q2 2026, its #172 holding.
- Handelsbanken Fonder first reported a position in Neurocrine Biosciences in Q2 2016 and has held it in 41 quarters since.
- 388 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.